原发性肝癌TACE及胸腺肽α_1治疗对T淋巴细胞亚群的影响

Effects of transcatheter arterial chemoembolization and thymosin peptide Alpha 1 on T lymphocyte subsets in hepatocellular carcinoma

目的:探讨TACE术后应用免疫调节剂胸腺肽α_1对患者T淋巴细胞亚群的影响。方法:收集2005年3月至2(009年1月收治的36例HCC患者作为研究对象,根据治疗方法不同将研究对象随机分为胸腺肽α_1治疗组(17例)和肝癌对照组(19例),另选择同期12例门诊健康体检者作为正常对照组。比较T细胞亚群变化及AFP、ALT、总胆红素、淋巴细胞总数等指标。结果:行TACE治疗后1、7 d,肝癌对照组患者体内CD3^+T、CD4^+T、CD8^+T、CD4^+/CD8^+比值与TACE治疗前比较,差异有统计学意义(P<0.05);胸腺肽α_1治疗组在TACE术后应用胸腺肽α_1治疗7 d后,CD4^+T、CD4^+/CD8^+、淋巴细胞的比值明显增加,与治疗前及肝癌对照组术后7 d比较,差异有统计学意义(P<0.05)。结论:TACE术后应用胸腺肽α_1可明显提高患者的细胞免疫水平,改善肝功能。

Objective：To determine the effects of thymosin peptide alpha 1, an immune regulator, on T lymphocyte subsets following transcatheter arterial ehemoembolization （TACE） in patients with hepatoeellular carcinoma. Methods： Thirty-six patients with HCC who received TACE between March 2005 and Janual7 2009 were randomly assigned to the thymosin peptide alpha 1 treatment group （n = 17） and control group （n = 19）. A total of 12 healthy subjects who received health check-up were recruited as normal controls. This allowed subsequent analysis on the changes in T cell subsets, alpha fetal protein （AFP） , alanine transferrase （ALT） , total bilirubin and lymphocyte count. Results： Compared with preoperative levels, TACE resulted in statistically different CD3 ＋ T and CD4 ＋ T,CD8 ＋ T, cell count and the ratio of CD4 ＋/CD8 ＋ cells （ all P 〈 0.05 ） at days 1 and 7 postoperatively. Treatment with thymosin peptide alpha 1 led to substantially augmented CD4 ＋ T and CD4 ＋ CD8 ＋ T count and the ratio of CD4 ＋/CD8 ＋ cells at day 7 following TACE compared with preoperative levels and that of control group （ all P 〈 0.05 ）. Conclusion ： Thylnosin peptide alpha 1 following TACE may improve the cellular immune function and liver function.